LenioBio GmbH is a biotechnology company specializing in protein expression solutions. LenioBio, which is headquartered in Düsseldorf, Germany, was founded in 2016 by business veterans and experts in protein expression. In March 2018, LenioBio signed a license agreement with Dow AgroSciences to launch their proprietary cell-free protein expression technology under LenioBio’s brand ALiCE®. LenioBio is currently developing the technology further, innovating through intelligent design to harness the power of nature to accelerate synthetic biology. The history and features of the technology behind ALiCE® are described in the Technology section.
At LenioBio, everything we do begins with our Mission: to provide our customers with innovative solutions that address their toughest challenges – more easily, quickly, and efficiently than ever before. This deep commitment is at the core of our name, Lenio, which derives from the Latin “to ease, alleviate, make better”.
LenioBio – Applied nature for better science.
Scientific Advisory Board
Dr. Lorenz M. Mayr.
Chief Technology Officer (CTO), GE Healthcare Life Sciences
Lorenz is working since May 2017 as Chief Technology Officer (CTO) for GE Healthcare Life Sciences and is responsible for all R&D investments, research programs, business growth strategy, technology innovation, and R&D talent development across all business areas (BioProcess, Imaging Diagnostics/Contrast Media, Research Tools and Applied Markets, Cell & Gene Therapy, New Opportunities).
Previously, he has been working as Vice President & Global Head, Reagents & Assay Development with responsibility for generation of all biological reagents and assay development activities across all therapeutic research areas at AstraZeneca.
Before that, he has been working as Executive Director at Novartis Pharma in Basel/Switzerland, at Bayer Pharma Research in Wuppertal/Germany, at Bayer Central Research in Leverkusen/Germany and at the M.I.T./Whitehead Institute in Cambridge/ Massachusetts (U.S.A.). He is lecturer for Biochemistry at the Martin-Luther University in Halle/Saale (Germany), has published over 60 papers in peer-reviewed journals and is member of several Scientific Advisory Boards (SABs).
He has received degrees in biochemistry, biophysics, molecular & cell biology at the University of Tubingen (Germany), University of Bayreuth (Germany) and the University of Colorado at Boulder (U.S.A.).
Prof. Dr. Stefan Schillberg
Head of Molecular Biology Department, Fraunhofer IME
Stefan is Member of the Institute Management (acting) and Head of Division Molecular Biotechnology of the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in Aachen, Germany. He received his Ph.D. in Molecular Biology from the RWTH Aachen University in 1994. His team has developed the cell-free expression system based on tobacco suspension cells and increased the productivity of this system to 3 mg per mL, thus outperforming any other eukaryotic cell-free platform.
Other activities in his laboratory focus on recombinant protein production in various hosts, downstream processing and recombinant protein analytics as well as metabolic engineering and the analysis of molecular factors affecting cell productivity. Dr. Schillberg has written more than 120 peer-reviewed scientific publications, published 26 book chapters and holds 20 filed or granted patents. He holds an honorary professorship at the Justus-Liebig-University in Giessen.